FDA approves AstraZeneca’s Imfinzi for limited-stage small cell lung cancer, cutting the risk of death by 27% in the ADRIATIC trial. Imfinzi shows median overall survival of 55.9 months versus ...

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.

Unite.AI is committed to rigorous editorial standards. We may receive compensation when you click on links to products we review. Please view our affiliate disclosure. Creating a strong brand identity ...

AUDI has unveiled a brand new logo for its latest EV launch - just days after luxury rival Jaguar was slammed for a major rebrand. The automaker is hoping to target young drivers with the change ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.

Below is Validea's guru fundamental report for ASTRAZENECA PLC (ADR) (AZN). Of the 22 guru strategies we follow, AZN rates highest using our P/E/Growth Investor model based on the published ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...

In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against the other profitable European stocks to buy. After the U.S. Presidential elections, the global ...